These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30637917)

  • 1. Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
    Dilly-Feldis M; Aladjidi N; Refait JK; Parrens M; Ducassou S; Rullier A
    Pediatr Blood Cancer; 2019 May; 66(5):e27571. PubMed ID: 30637917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
    Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
    Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Gilardin L; Amorim S; Bernard S; Ravdan O; Thieblemont C; Brice P
    Bull Cancer; 2018 Dec; 105 Suppl 1():S50-S58. PubMed ID: 30595199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
    Armand P; Shipp MA; Ribrag V; Michot JM; Zinzani PL; Kuruvilla J; Snyder ES; Ricart AD; Balakumaran A; Rose S; Moskowitz CH
    J Clin Oncol; 2016 Nov; 34(31):3733-3739. PubMed ID: 27354476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review.
    Dada R
    Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
    Sakakibara A; Kohno K; Eladl AE; Klaisuwan T; Ishikawa E; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Kato S; Asano N; Nakamura S; Satou A
    Histopathology; 2018 Jun; 72(7):1156-1163. PubMed ID: 29380399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Where does PD-1 blockade fit in HL therapy?
    Herrera AF
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
    Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
    Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
    de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
    Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Checkpoint inhibitors in Hodgkin lymphoma].
    Sasse S; Momotow J; Engert A
    Internist (Berl); 2020 Jul; 61(7):660-668. PubMed ID: 32462248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Hainfellner JA; Birner P; Raderer M; Preusser M
    Clin Neuropathol; 2014; 33(1):42-9. PubMed ID: 24359606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.
    Jalali S; Price-Troska T; Bothun C; Villasboas J; Kim HJ; Yang ZZ; Novak AJ; Dong H; Ansell SM
    Blood Cancer J; 2019 Feb; 9(3):22. PubMed ID: 30783096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
    Ansell SM
    Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.